The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells

Files in this item

This item appears in the following Collection(s)

Available in accordance with the Publisher Policy. Please refer to the publisher's site for terms of use.

Search Repository


My Account

Statistics